ORDER NOW! The MyRisk Test is the only germline core panel with 100% of genes strongly recommended by ASCO guidelines2,3
Delivering comprehensive care at every step of the patient journey with germline and tumor genomic insights to assess hereditary cancer risk, guide treatment selection, and evaluate recurrence risk—all in one streamlined solution.
Myriad Oncology offers comprehensive germline and tumor genomic tests that provide clinically actionable insights, helping to tailor treatments for each patient’s unique cancer journey—maximizing their chance for a healthier future.
I’m a provider
I’m a patient
From risk assessment to therapy selection, Myriad Oncology offers integrated germline and tumor genomic tests that enable a truly personalized approach to cancer prevention and treatment.
Risk Assessment and prevention
Individualized management based on accurate hereditary cancer risk assessment
Surgery guidance
Appropriate surgery decisions based on hereditary cancer syndromes and risk of second primary cancer
Initial treatment guidance
Active surveillance and treatment intensity decisions based on guideline-supported molecular insights
Adjuvant therapy guidance
Adjuvant treatment decisions based on comprehensive guideline-supported germline and tumor genomic testing
Targeted therapy selection
FDA-approved therapies and clinical trial availability based on comprehensive germline and tumor genomic results
Management planning
Management updates and assessment of family members based on hereditary cancer syndromes
Myriad Oncology provides a comprehensive suite of services and workflow solutions that simplify germline and tumor genomic testing, all at no additional cost to the clinic or patient.
Pre- and post-test education as live, point-of-care sessions with a board-certified Genetic Counselor
Transparent pricing with personalized cost estimates, financial assistance, and other affordability options, including direct pay
Consolidated germline and tumor genomic results are available, on average, 14 days after our lab receives the sample
The Myriad Management Tool streamlines germline and tumor genomic results into an easy-to-follow report
Medical Science Liaisons support providers and their teams in answering clinical, testing, and results-related questions
Myriad’s Variant Classification Program includes a Lifetime Reclassification Commitment to send amended reports if a variant of uncertain significance (VUS) is reclassified and is clinically actionable
Comprehensive germline and tumor genomic biomarker testing from a single, trusted source
Germline hereditary cancer test analyzing 63 clinically-validated genes associated with over 11 cancer types—aligned with national oncology guidelines.
The Precise Tumor® Test is a pan-cancer, comprehensive laboratory test that uses state-of-the-art, next-generation sequencing to discover and target important variants within tumors.
Genomic prognostic test for patients newly diagnosed with early-stage, estrogen-receptor-positive, HER2-negative breast cancer.
The Prolaris® Test is a molecular diagnostic test that helps determine the aggressiveness of a prostate cancer tumor to guide the best treatment decisions for prostate cancer patients.
The most comprehensive FDA-approved tumor test that determines HRD status in women with ovarian cancer.
FDA-approved germline companion diagnostic test for patients with breast, ovarian, pancreatic and prostate cancer.
FDA-approved assay to identify patients with ovarian cancer who may qualify for treatment with mirvetuximab*
Offered together with Precise Tumor™ to measure protein expression and identify patients who may benefit from immunotherapy
The MyRisk® Hereditary Cancer Test focuses exclusively on genes backed by clinical evidence and cited in national oncology guidelines—so every result has the potential to inform care.1-3
of genes strongly recommended by ASCO guidelines are tested to help ensure no relevant findings are missed1-3
of genes tested are cited in national oncology guidelines, helping to avoid the uncertainty associated with non-actionable results1-3
The majority of patients face no out-of-pocket costs for MyRisk testing8
Patients will know what their costs are—if any—before the test is run.
Myriad offers assistance to manage out-of-pocket costs as well as a direct pay option.
Myriad conducts industry-leading, innovative genetic research and testing to further the science of care. Our scientific studies have been published in prominent journals and at global conferences and feature breakthrough insights for improved patient treatments and outcomes
Stay up to date on the latest industry information on our blog featuring healthcare professionals, patients, and Myriad leadership.
Request more information from our team.
Request more information about how Myriad Oncology can benefit you/your patients.
Request more information about how Myriad’s Oncology solutions can benefit you/your patients.
By submitting your personal information, you agree to be contacted with newsletters, marketing or promotional materials, and other information that may be of interest to you. You may opt-out of receiving communications from us by following the unsubscribe link or the instructions provided in the communication we send. For further information on our privacy practices and commitment to protecting your privacy, please visit our Privacy Notice.
Contact Information
©2025 Myriad Genetics, Myriad Oncology, MyRisk, Precise Tumor, MyChoice, Prolaris, BRACAnalysis CDx, RiskScore, and their respective logos, are either trademarks or registered trademarks of Myriad Genetics, Inc. and its subsidiaries in the United States and other jurisdictions. EndoPredict and the EndoPredict logo are either trademarks or registered trademarks of Eurobio Scientific. Eurobio Scientific has licensed the EndoPredict test to Myriad Genetics in select territories.